TC Biopharm (Holdings) Plc (NASDAQ:TCBP) Short Interest Up 474.1% in January

TC Biopharm (Holdings) Plc (NASDAQ:TCBP) was the recipient of a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 181,400 shares, a growth of 474.1% from the December 31st total of 31,600 shares. Based on an average daily volume of 2,260,000 shares, the short-interest ratio is currently 0.1 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright cut their price target on TC Biopharm from $5.60 to $2.40 and set a “buy” rating on the stock in a report on Friday, December 6th.

TC Biopharm Trading Down 6.9 %

Shares of TC Biopharm stock traded down $0.02 on Tuesday, hitting $0.28. The company had a trading volume of 399,167 shares, compared to its average volume of 873,940. TC Biopharm has a 52 week low of $0.25 and a 52 week high of $26.16. The business has a 50-day simple moving average of $0.46 and a 200-day simple moving average of $2.73.

About TC Biopharm

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers.